Johnson & Johnson Tops Q4 Earnings Forecast, But Light Revenue, Remicade Sales Hit Shares

 

Johnson & Johnson Tops Q4 Earnings Forecast, But Light Revenue, Remicade Sales Hit Shares

Johnson & Johnson said sales of its key arthritis treatment, Remicade, slipped 16% from last year, pressuring overall revenues and clouding a fourth quarter earnings beat.

More Johnson & Johnson Tops Q4 Earnings Forecast, But Light Revenue, Remicade Sales Hit Shares Videos

Leave a Reply